Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| HIV-1 Integrase (EC 2.7.7.) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| HIV-1 Integrase (EC 2.7.7.) Products under Development by Stage of Development | 8 | 1 |
| HIV-1 Integrase (EC 2.7.7.) Products under Development by Therapy Area | 9 | 1 |
| HIV-1 Integrase (EC 2.7.7.) Products under Development by Indication | 10 | 1 |
| HIV-1 Integrase (EC 2.7.7.) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| HIV-1 Integrase (EC 2.7.7.) Products under Development by Companies | 13 | 2 |
| HIV-1 Integrase (EC 2.7.7.) Products under Development by Universities/Institutes | 15 | 2 |
| HIV-1 Integrase (EC 2.7.7.) Therapeutics Assessment | 17 | 6 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| HIV-1 Integrase (EC 2.7.7.) Companies Involved in Therapeutics Development | 23 | 5 |
| Critical Outcome Technologies Inc. | 23 | 1 |
| Gilead Sciences, Inc. | 24 | 1 |
| Merck &Co., Inc. | 25 | 1 |
| TGV-Laboratories | 26 | 1 |
| ViiV Healthcare Limited | 27 | 1 |
| HIV-1 Integrase (EC 2.7.7.) Drug Profiles | 28 | 21 |
| (cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide fumarate) Drug Profile | 28 | 5 |
| (dolutegravir sodium + rilpivirine hydrochloride) Drug Profile | 33 | 1 |
| Antisense RNAi Oligonucleotide to Inhibit HIV-I Integrase for HIV Drug Profile | 34 | 1 |
| cabotegravir sodium Drug Profile | 35 | 3 |
| cabotegravir sodium + rilpivirine hydrochloride Drug Profile | 38 | 1 |
| elvitegravir Drug Profile | 39 | 2 |
| M-522 Drug Profile | 41 | 1 |
| M-532 Drug Profile | 42 | 1 |
| MK-2048 Drug Profile | 43 | 1 |
| Small Molecule to Inhibit HIV-1 Integrase for HIV infection Drug Profile | 44 | 1 |
| Small Molecule to Inhibit Integrase for HIV Drug Profile | 45 | 1 |
| Small Molecules to Inhibit HIV-1 Integrase for HIV-1 Infection Drug Profile | 46 | 1 |
| Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection Drug Profile | 47 | 1 |
| T-169 Drug Profile | 48 | 1 |
| HIV-1 Integrase (EC 2.7.7.) Dormant Projects | 49 | 1 |
| HIV-1 Integrase (EC 2.7.7.) Discontinued Products | 50 | 1 |
| HIV-1 Integrase (EC 2.7.7.) Featured News &Press Releases | 51 | 18 |
| Feb 24, 2016: ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir | 51 | 1 |
| Feb 23, 2016: ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment | 52 | 1 |
| Jan 26, 2016: AHF Files Federal Lawsuit Against Gilead to Invalidate Patents on Key AIDS Drug | 53 | 1 |
| Dec 07, 2015: Health Canada Issues Notice of Compliance for Gilead's Single Tablet Regimen Genvoya (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection | 54 | 1 |
| Nov 23, 2015: European Commission Grants Marketing Authorization for Gilead s Single Tablet Regimen Genvoya (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV-1 Infection | 55 | 1 |
| Nov 05, 2015: U.S. Food and Drug Administration Approves Gilead s Single Tablet Regimen Genvoya (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection | 56 | 2 |
| Nov 03, 2015: ViiV Healthcare announces positive headline results from a study of two drug injectable regimen for HIV maintenance therapy | 58 | 1 |
| Oct 22, 2015: Gilead Announces Phase 3 Results for Genvoya (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), an Investigational Once-Daily Single Tablet Regimen for HIV | 58 | 2 |
| Sep 25, 2015: European CHMP Adopts Positive Opinion for Gilead s Single Tablet Regimen Genvoya for the Treatment of HIV | 60 | 1 |
| Jul 21, 2015: Gilead Announces Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF) | 61 | 2 |
| May 06, 2015: ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy | 63 | 1 |
| Apr 15, 2015: Critical Outcome Technologies Receives First U.S. Patent For Next Generation HIV Treatment | 64 | 1 |
| Feb 26, 2015: Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide | 64 | 3 |
| Jan 15, 2015: Long-acting drug effectively prevents HIV-like infection in monkeys | 67 | 1 |
| Nov 06, 2014: Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV | 68 | 1 |
| Appendix | 69 | 2 |
| Methodology | 69 | 1 |
| Coverage | 69 | 1 |
| Secondary Research | 69 | 1 |
| Primary Research | 69 | 1 |
| Expert Panel Validation | 69 | 1 |
| Contact Us | 69 | 1 |
| Disclaimer | 70 | 1 |